Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (40)

I-03Pascal Schulthess

Frequency-domain derived optimisation of cell cycle specific cancer treatment

Wednesday 10:10-11:40

I-07Shringi Sharma

A Joint Model to Evaluate the Relationship between Lymph Node Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

Wednesday 10:10-11:40

I-08Dmitry Shchelokov

A semi-mechanistic model of targeted therapy for melanoma

Wednesday 10:10-11:40

I-20Mark Stroh

Customizing the distribution of a masked, tumor-activated antibody with quantitative systems pharmacology

Wednesday 10:10-11:40

I-28Sonya Chapman

Dose Fractionation Study Design and PK/PD Model Analysis to Establish the Quantitative Pharmacology of Selective Aurora A Kinase Inhibition by Compound X and LY3295668

Wednesday 10:10-11:40

I-52Johan Wallin

Validation of Xenograft Dose Predictions for Clinical Efficacy in NSCLC

Wednesday 10:10-11:40

I-59Justin Wilkins

Population pharmacokinetic analysis of M7824 (MSB0011359C) in different cancer types

Wednesday 10:10-11:40

I-60Francis Williams Ojara

A time-to-event analysis of paclitaxel-related peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first line chemotherapy

Wednesday 10:10-11:40

I-63Gudrun Wuerthwein

Population pharmacokinetics for PEGylated asparaginase Oncaspar® in children with ALL: differences between protocol parts and predictivity

Wednesday 10:10-11:40

I-65Feifan Xie

A model-based analysis of the kinetics of leukocytes in stage III ovarian cancer patients treated with neo-adjuvant chemotherapy, cytoreductive surgery and cisplatin-based intraperitoneal chemoperfusion

Wednesday 10:10-11:40

II-08Yan Feng

A Mixture Tumor Growth Dynamic (TGD) Model to Describe Differential Patterns of Longitudinal Tumor Response of Advanced Melanoma Patients Treated with Ipilimumab

Wednesday 15:50-17:20

II-09Fernandez Teruel Carlos

Drug exposure / response model for neutropenia with lurbinectedin in cancer patients

Wednesday 15:50-17:20

II-15Matthias Frei

Distinguishing myelosupressive response of a paclitaxel –radium-223 combination using a model-based analysis of an individual cross-over phase-Ib trial in cancer patients with bone lesions

Wednesday 15:50-17:20

II-22Glenn Gauderat

Reversing resistance to anticancer treatment supported by pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in xenograft mice

Wednesday 15:50-17:20

II-46Joy Hsu

Population Pharmacokinetic and Exposure-Efficacy/Safety Analyses for the Confirmation of Alectinib 600 mg BID Dose Regimen in the Global ALK Inhibitor-Naïve Population

Wednesday 15:50-17:20

II-52Julie Janssen

Semi-physiological Pharmacokinetics of Bortezomib in Pediatric Patients with Acute Lymphoblastic Leukemia

Wednesday 15:50-17:20

II-57Martin Johnson

Artificial neural networks can facilitate the analysis and prediction of longitudinal tumour size data: an example from a non-small cell lung cancer phase III study

Wednesday 15:50-17:20

II-63Astrid Jullion

Dosing Regimen selection supported by population PKPD model of thrombocytopenia

Wednesday 15:50-17:20

II-64Yunseob Jung

A population pharmacokinetic model of methotrexate in Korean people

Wednesday 15:50-17:20

II-69Yuri Kheifetz

Integral individualized model of hematopoiesis explains and predicts joint dynamics of thrombocytes, granulocytes and lymphocytes under different chemotherapeutic and adjuvant treatments scenarios

Wednesday 15:50-17:20

III-15Guillaume Baneyx

Target-mediated drug disposition modeling of lacnotuzumab in healthy volunteers and patients with advanced malignancies and triple negative breast cancer.

Thursday 09:55-11:30

III-36Tim Cardilin

Modeling of radiation therapy and radiosensitizing agents in tumor xenografts

Thursday 09:55-11:30

III-37Evelina Cardoso

Population pharmacokinetic analysis of erlotinib in cancer patients affected by NSCLC

Thursday 09:55-11:30

III-41Anne Chain

Extension of population pharmacokinetic analysis of pembrolizumab to paediatric patients patients with classical Hodgkin lymphoma

Thursday 09:55-11:30

III-46Wenjun Chen

Modeling the antitumor efficacy and pharmacokinetic/pharmacodynamic interaction between docetaxel and cabozantinib in human prostate cancer xenograft mouse models

Thursday 09:55-11:30

III-66Elien De Thaye

In vitro data supporting circulating CCCK18 as potential pharmacodynamic biomarker in ovarian cancer

Thursday 09:55-11:30

III-67Aurelia de Vries Schultink

Therapeutic drug monitoring of endoxifen in ER-positive breast cancer patients: comparing data from clinical practice to model-based predictions.

Thursday 09:55-11:30

III-70Oleg Demin Jr

Quantitative Systems Pharmacology Modeling of CAR-T Therapy and T Cell Engaging Bispecific Antibodies: B-cell Acute Lymphoblastic Leukemia Case Study

Thursday 09:55-11:30

III-73Anne-Gaelle Dosne

Optimizing Biomarker-Based Dosing Algorithm for Erdafitinib through PK-PD Modeling and Simulations

Thursday 09:55-11:30

III-75Vincent Dubois

Comparative attributes of a semimechanistic and an empirical population PK model for durvalumab, a fully human anti-PD-L1 monoclonal antibody

Thursday 09:55-11:30

III-76Miro Eigenmann

Dynamic in vitro PKPD assessment to improve pharmacological response profiling of T-cell bispecifics

Thursday 09:55-11:30

IV-16Rubin Lubomirov

Population pharmacokinetic-based targeted exome sequencing (PopPK-TES) approach to assess the impact of genetic variants on pharmacokinetics of lurbinectedin in patients with advanced cancer

Thursday 15:10-16:40

IV-17Sreenath M Krishnan

Accuracy in the estimation of the hazard in simultaneous and sequential estimation approaches of tumor size and overall survival (OS) modeling

Thursday 15:10-16:40

IV-27Christophe Meille

PKPD modeling of preclinical anti-tumor activity translates to first-in-human phase I study of MDM2 inhibitor HDM201

Thursday 15:10-16:40

IV-31Jonathan Mochel

Modeling Primary Tumor Growth in a Xenograft Mouse Model of Non-Small Cell Lung Cancer Treated With Pemetrexed-Cisplatin and Bevacizumab

Thursday 15:10-16:40

IV-34Ricardo Nalda-Molina

Population Pharmacokinetics of Hyperthermic Intraoperative Peritoneal Oxaliplatin in Wistar Rats

Thursday 15:10-16:40

IV-35Antonina Nikitich

Immune Response Template for Quantitative Systems Pharmacology Modeling: Description of Co-inhibitory and Co-stimulatory Receptors Interaction

Thursday 15:10-16:40

IV-39Ana Novakovic

Simulation based assessment of flat dose regimen of an anti-PDL1 antibody: Case study of avelumab

Thursday 15:10-16:40

IV-41Katharina Och

A pharmacokinetic/pharmacodynamic model of cyclosporine A and its nephrotoxicity in patients after hematopoietic stem cell transplantation

Thursday 15:10-16:40

IV-65Alicja Puszkiel

Quantitative evaluation of the impact of CYP2D6 genetic polymorphisms on pharmacokinetics of tamoxifen and its metabolites in breast cancer patients

Thursday 15:10-16:40